Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways by Saw, Constance Lay-Lay et al.
REVIEW Open Access
Anti-cancer and potential chemopreventive




1,2,3, Ah-Ng Tony Kong
1,2*
Abstract
This article reviews recent basic and clinical studies of ginseng, particularly the anti-cancer effects and the potential
chemopreventive actions by activating the transcriptional factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or
NFE2L2)-mediated anti-oxidative stress or anti-inflammatory pathways. Nrf2 is a novel target for cancer prevention as
it regulates the antioxidant responsive element (ARE), a critical regulatory element in the promoter region of genes
encoding cellular phase II detoxifying and anti-oxidative stress enzymes. The studies on the chemopreventive effects
of ginseng or its components/products showed that Nrf2 could also be a target for ginseng’s actions. A number of
papers also demonstrated the anti-inflammatory effects of ginseng. Targeting Nrf2 pathway is a novel approach to
the investigation of ginseng’s cancer chemopreventive actions, including some oxidative stress and inflammatory
conditions responsible for the initiation, promotion and progression of carcinogenesis.
Background
Ginseng protects the cardiovascular system, stimulates
the central nervous system [1] and possesses anti-cancer
activities [2,3] inhibiting human gastric adenocarcinoma
[4] and human breast carcinoma [5]. Therefore, ginseng
is a potential cancer preventive agent [6].
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or
NFE2L2) is a key regulator of the antioxidant responsive
element (ARE)-mediated gene expression and therefore
a potential anti-cancer target for chemopreventive com-
pounds [7], including ginseng [8-10]. However, concerns
have been raised for possible inappropriate claims of
ginseng products [11,12]. This article reviews the poten-
tial chemopreventive actions of ginseng via the Nrf2 sig-
nalling pathway and the potential molecular mechanism
of ginseng’s anti-cancer effects.
Literature search
A full literature search (up to 2010) was conducted dur-
ing November 2009 till April 2010 with ‘ginseng’ as the
search keyword was performed in PubMed and the Chi-
nese National Knowledge Infrastructure (CNKI). Other
keywords used in the search included ‘ginseng’, ‘Nrf2’,
‘chemoprevention’, ‘cancer prevention’, ‘clinical studies’
and ‘anti-cancer’. A total of 3917 and 147 papers from
PubMed and CNKI respectively were retrieved and
screened for anti-cancer clinical studies with ginseng.
Seven published articles were found in PubMed with the
keywords ‘ginseng’ and ‘Nrf2’ including a paper on
Angelica sinensis (Danggui) [13].
Ginseng in Chinese medicine
In Chinese medicine, a disorder is often a manifestation
of an imbalance between yin and yang and/or changes
in the pathogenic and antipathogenic qi. Ginseng is the
drug of choice for replenishing qi, especially in the case
of qi collapse. Major Chinese medicinal uses of ginseng
and its commercial products and their indications are
provided in Table 1.
Clinical studies on ginseng as adjuvant therapy for cancer
Ginseng possesses preventive and therapeutics effects on
cancer [14,15]. Ginseng is used to treat cancer or to
reinforce the effects and/or reduce the side effects of
chemotherapy [16,17]. Ginseng polysaccharides and gin-
senosides are the main ingredients contributing to anti-
cancer action of ginseng [18-21]. Ginseng boosts the
patient’s immunity, suppresses the proliferation of
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any medium, provided the original work is properly cited.tumour cells, inhibits the formation of new blood vessels
in tumours, induces apoptosis of tumour cells, anti-
metastasis of tumour and immunomodulation [3,6].
Additional file 1 lists recent clinical studies of ginseng
products as adjuvant therapy to chemotherapy and
radiotherapy in China [22-27].
Significance of the Nrf2-ARE signalling pathway in cancer
chemoprevention
Carcinogenesis involves multiple steps including transi-
tion of normal cells to pre-initiated cells and ultimately
invasive carcinoma, providing ample opportunities for
chemoprevention. In general, tumour development fol-
lows three distinct yet closely interrelated phases (I-III),
namely initiation, promotion and progression [28,29].
When cells are exposed to oxidative stress, DNA may go
through oxidative damage [30] coupled with persisting
inflammation [31] as well as formation of DNA adducts,
leading to increased genomic instability, enhanced neo-
plastic transformation and ultimately cancer (Figure 1).
Various cancer chemopreventive compounds, including
natural dietary and synthetic compounds, are found to be
effective in preventing cancer formation at all of these
three developmental stages [32-34] (Figure 1). Curcumin
is one of such natural dietary chemopreventive com-
pounds with promising findings from clinical trials
[35,36]. When the cell is exposed to oxidative stress such
as reactive oxygen species (ROS), reactive nitrogen spe-
cies (RNS) or carcinogenic species, induction of phase I,
phase II and phase III enzymes/transporters occur
[37,38]. Carcinogens are typically metabolized via oxida-
tion and reduction by phase I enzymes [39]. The result-
ing products are conjugated with endogenous cofactors
such as glutathione (GSH) by glutathione S-transferase
(GST), a phase II enzyme forming water soluble products
that can be easily excreted [39,40]. Induction of other
phase II enzymes such as uridine-diphospho-glucurono-
syltransferases (UGT) may also enhance the excretion of
carcinogens such as heterocyclic aromatic amines, the
well-known genotoxic chemicals formed during prepara-
tion of foods [41,42].
The induction of phase II enzymes can be attributed
to the transcriptional control of the ARE by Nrf2 [7].
Nrf2 is a key regulator of ARE-mediated gene expres-
sion and a potential target for chemopreventive com-
pounds [43-45]. Nrf2 is inhibited in the cytoplasm by
the anchor protein Kelch-like ECH-associated protein-1
(Keap1), a cytosolic protein that inhibits Nrf2 signalling
by promoting Nrf2 degradation through proteasomal
pathway [46]. In the presence of oxidative stress or che-
mical inducers, Nrf2 is released from Keap1 inhibition,
translocates to the nucleus and binds to ARE consensus
sequences [47]. Activation of Nrf2 by chemopreventive
agents influences the expression of phase II and anti-
oxidative stress enzymes such as heme oxygenase 1
(HO-1) [48]. HO-1 catalyzes the degradation of heme to
carbon monoxide, iron and biliverdin and is thought to
be essential in cellular defensive mechanisms and is
implicated in various pathophysiological conditions such
as inflammation, atherosclerosis, neurodegenerative dis-
eases and cancers [49]. Since the first isolation of Nrf2
in 1995, the function of Nrf2 has been studied widely
[50]. It appears that the most important role of Nrf2 is
activating the ARE-mediated anti-oxidative responses
[47]. The current understanding of the molecular Nrf2-
ARE pathway is illustrated in Figure 2 as a schematic
presentation of the proposed mechanism by which ARE
and its downstream target enzymes are induced upon
transcriptional activation [7,47,51,52]. Under normal
physiological conditions, ROS and other endogenous
reactive molecules are also constantly being produced
during normal aerobic metabolism, based on numerous
experimental evidence, such constitutive gene expression
is also thought to be under the regulation of ARE by
Nrf2 [47]. Interestingly, many chemopreventive com-
pounds, including ginseng, are inducers of ARE. Addi-
tional file 2 lists the studies of ginseng and its extract
[53-56] in activating the Nrf2-ARE pathway.
Table 1 Use of ginseng in Chinese medicine
Actions Indications Chinese medicine products
To replenish the
primordial qi
Collapse due to prostration of primordial qi, exhibiting extremely cold
limbs, sweating, vertigo and shortness of breath.
Shenfu tang - decoction of ginseng and Aconiti
Lateralis;
Sinijia renshen tang - decoction of ginseng for
treating yang exhaustion.
To nourish the spleen
and stomach
Spleen and stomach qi deficiency complicated by dampness, exhibiting
weakness of limbs, emaciation, indigestion, vomiting or diarrhoea,
fullness in the epigastrium and chest.
Shenlingbaizhu san - powder of ginseng, Poria
and Atractylodis Macrocephalae;




Impairment of both qi and yin, exhibiting lassitude, shortness of breath,
excessive perspiration, dry throat, thirst; also for long-standing cough
due to lung deficiency.
Shengmai yin - liquid of ginseng, Radix





Disorders involving heart and spleen deficiency, exhibiting palpitation,
amnesia, insomnia, poor appetite, fatigue; also for cases of hemafecia,
metrorrhagia and metrostaxis.
Guipi wan - ginseng pills for invigorating spleen
and nourishing the heart;
Renshen yangrong wan - pills of ginseng for
nourishing qi and yin.
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Kim et al. reported that ginseng extract induced the ele-
vation of catalase and superoxide dismutase activities in
sedentary male patients [57]. Another study reported
significant reduction of oxidative stress biomarkers such
as F2-isoprostane and 8-hydroxy-deoxyguanosine in
healthy patients after oral administration of ginsenoside-
enriched Panax quinquefolius (American ginseng)
extract [58]. As the study did not measure specific
enzymes, it is not clear whether the reduction of these
markers was due to the induction of antioxidant
enzymes. As an in vivo study found that ginsenosides
induced cytochrome (CYP) P450 1A1 which plays an
important role in xenobiotic metabolism as well as in
carcinogenesis [59], the drug interactions between gin-
seng and conventional drugs including chemotherapeu-
tic agents should be recognized. It was postulated that
ginsenoside competed with aryl hydrocarbons for both
the aryl hydrocarbon receptor and CYP1A1, which may
explain ginseng’s chemopreventive properties [59].
Another study reported that a water extract of ginseng
inhibited benzo[a]pyrene (BaP)-induced hepatotoxicity
and CYP1A1 expression and reversed the reduction of
GSH content and GST activities induced by BaP in rats
[8]. Moreover, various isoforms of phase II gene GSTs
were significantly induced by the ginseng extract via
activating the Nrf2-ARE pathway. Therefore, the latter
in vivo study [8] showed great promise for future studies
of ginseng and chemoprevention in chemical-induced
animal carcinogenesis models.
The role of Nrf2 is not only implicated in the induc-
tion of the antioxidant and phase II genes, but is also
involved in anti-inflammation. One of the key transcrip-
tional factors in inflammatory response is the nuclear
factor-kappa-B (NF-kB) and many chemopreventive
compounds have been reported that those compounds
work through activating the Nrf2 pathway also suppres-
sing inflammatory activities [44,60-64]. Glutathione per-
oxidase 2 (Gpx2) prevented the exacerbation of
inflammation induced by cyclooxygenase-2 (COX-2)
expression and inflammation driven initiation of carci-
nogenesis [65]. Various ginsenosides inhibited inducible
nitric oxide synthase (iNOS)-induced NO production
[66] and down-regulated COX-2 expression [67]. Inter-
estingly, ginseng induced the expression of g-glutamyl-
cystein ligase (g-GCL) and enhanced production of GSH
Figure 1 Carcinogenesis is a multiple steps process. The initiation step is started by the transformation of the normal cell into a cancer cell
(initiated cell). These cells undergo tumour promotion into preneoplastic cells, which progress to neoplastic cells. Inflammation and oxidative
stress, together with the accumulation of genetic alterations over a lifetime of patients, will result in the formation of cancer. It is important to
take note that in reality, cancer may arise without proceeding through each of these steps. Chemopreventive agents can interfere with different
steps of this process. Some agents inhibit metabolic activation of the procarcinogens to their ultimate electrophilic species, or their subsequent
interaction with DNA. These agents therefore block tumour initiation (blocking agents). Alternatively, blocking agents can stimulate the
detoxification of carcinogens, leading to their excretion from the body. Other agents suppress (suppressing agents) the later steps (promotion
and progression). Some agents can act as both blocking and suppressing agents.
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expect that Nrf2 would be induced by ginsenoside Rd as
well, however, it was reported that ginsenoside Rd
increased the nuclear level of p65, which is the subunit
of NF-kB complex, but not the level of Nrf2 [68]. Such
observation is rather uncommon, as other reports have
shown that ginsenosides are suppressing NF-kB which
will be presented below. Therefore, effects of ginseno-
side Rd on NF-kB pathway warrants additional detailed
experiment for verification. One of the metabolite of
ginsenoside, 20(S)-protopanaxatriol inhibited iNOS and
COX-2 expressions through inactivation of NF-kB [69].
Evidence supports the notion that blocking NF-kB is an
important target for the control of inflammation and
cancer [70,71]. The interplays between Nrf2 and NF-kB
signalling pathways were studied in our laboratory with
a bioinformaticsa p p r o a c h[ 7 2 ]a n dw i t ha nN r f 2 - / -
mouse model [61,73]. We found potential common
members involved in the crosstalk between Nrf2 and
NF-kB signalling pathways, such as some of the
upstream mitogen-activated protein kinases (MAPKs).
Increasing evidence supports the existing crosstalk
between Nrf2 pathway and anti-inflammation
[61,73-77]. It is likely that some of the components in
ginseng targeting the Nrf2 pathway and enhancing the
expression of ARE-mediated antioxidant and phase II
genes would suppress the aberrant inflammatory
responses regulated by the NF-kB pathway concomi-
tantly (Figure 3).
Future studies
In future studies, it would be important to correlate the
oxidative stress markers and the development of oxida-
tive stress induced-diseases such as cancer in chemopre-
ventive studies using ginseng/ginseng products. Properly
designed long-term clinical studies should be performed
to investigate the chemopreventive activities of ginseng,
particularly the Nrf2-related antioxidant and phase II
detoxifying enzymes as many cancer patients worldwide,
have been using ginseng for boosting the immunity or
general well-being during chemotherapy, radiotherapy
or post-surgery.
Conclusion
The anti-cancer and chemopreventive actions of ginseng
could be exerted through activating the Nrf2 anti-oxidative
Figure 2 Schematic presentation of Nrf2-ARE pathway. In the cytoplasm, under basal level, newly synthesized Nrf2 is constitutively bound to
Keap1 forming a dimer, Nrf2-Keap1. Keap1 is a cytosolic protein that inhibits Nrf2 signalling by promoting Nrf2 degradation through proteasomal
pathway. When oxidants such as ROS, RNS and dietary chemopreventive compounds react with redox reactive cysteines in Keap1, Nrf2 will be
released from Keap1, hence allowing the transcriptional factor Nrf2 to translocate to the nucleus. In the nucleus, Nrf2 dimerizes with basic
leucine zipper partners (bZip) such as small MAF-family proteins and bind to ARE, which is located in the promoter of the phase II and
antioxidative genes, triggering the transcription of ARE-regulated genes. The critical role of Nrf2 in protecting cells/subjects from neoplastic
transformation when subject to oxidative stress and carcinogens is performed by enhancing the expression of detoxifying metabolizing enzymes
and maintaining oxidative stress homeostasis by producing antioxidant enzymes. Application of chemopreventive compounds can further
enhance the expression of phase II detoxifying and antioxidant enzymes by up-regulating the Nrf2-ARE expression.
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effects of ginseng in Nrf2-mediated induction of phase II/
antioxidant enzymes would elucidate the action mechan-
ism of ginseng in cancer chemoprevention.
Additional material
Additional file 1: Clinical studies of ginseng Chinese medicine
products as adjuvant therapy to cancer treatments.
Additional file 2: Preclinical studies on ginseng and its extracts
showing molecular activities on Nrf2 activation for potential
chemopreventive use.
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